Search

TGF-beta1 has been known to suppress the growth of gastric cancer cells. Interestingly, TGF-beta1 treatment increased the proliferation of human gastric cancer cell line, SNU-216 cells, while it reduced the proliferation of other tumor cells including SNU-620 cells. TGF-beta1-mediated down-regulation of c-Myc and induction of p21CIP1 were observed in SNU-620, but there was no change in SNU-216 in response to TGF-beta1. Similarly, TGF-beta1 receptors were upregulated by TGF-beta1 treatment in SNU-620, but they were not responded in SNU-216. By a single strand conformation polymorphism analysis, a repeated insertion of 37 nucleotides in the exon 8 of Smad4, resulting in premature termination at codon 362, was found in SNU-216. Furthermore, this truncated Smad4 functioned as a dominant negative form in TGF-beta1-mediated reporter activity and TGF-beta1 receptor expression. However, the proliferation of tumor cells was not affected by Smad4 mutation, but it was modulated by PD98059. Taken together, a mutation in Smad4 in addition to mitogen-activated protein kinase altered the TGF-beta1-mediated signaling, which is one of key events of gastric tumorigenesis. [ABSTRACT FROM AUTHOR]

As an effort to identify immune suppressive molecules in gastric cancer cells, a signal sequence trap was employed. Among the genes identified, 9-27 gene was highly expressed in gastric tumor tissues and in cancer cell lines. It was induced by IFN-gamma treatment, but not by TNF-alpha or TGF-beta1 treatment. The overexpression of 9-27 in the gastric cancer cells rendered tumor cells more resistant to natural killer cells. In addition, the 9-27-overexpressed cells showed an increased migration and an invasive capacity when compared with the control cells. Taken together, these data indicate that 9-27 plays a role in malignant progression by suppressing natural killer cells and by increasing the invasive potential of gastric cancer cells.